News & Events
-
August 29, 2023
Externally-Led Patient Focused Drug Development
C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) and the PKD Foundation will be hosting an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for Autosomal Recessive Polycystic Kidney Disease (ARPKD) on Tuesday, August 29th. EL-PFDD meetings bring together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, physicians, and researchers who are...... -
June 25, 2023 - June 29, 2023
DIA 2023 Global Annual Meeting | ILLUMINATE
The DIA 2023 Global Annual Meeting invites industry, regulatory government, academics, and patients to network, problem-solve, and discuss global and local challenges facing the life sciences community. Hosted in Boston, key C-Path personnel will be on-hand to discuss and view the many different perspectives offered at this event, while highlights expertise across the globe to...... -
June 14, 2023 - June 15, 2023
CeBil Symposium
The CeBil symposium marks the conclusion of the Novo Nordisk Foundation’s Collaborative Research Program in Biomedical Innovation Law (the CeBIL-program), which has been running since 2018. Leading international experts will discuss the ethical, legal, and social, and policy implications (ELSPI) of selected challenges and opportunities in the health and life sciences. This event has two...... -
June 2, 2023
SARC Annual Meeting ASCO 2023
Leading into the annual meeting of the American Society of Clinical Oncology (ASCO), SARC will host the first of two 2023 SARC semiannual meetings. C-Path’s Executive Director of the CURE Drug Repurposing Collaboratory, Marco Schito, and Senior Project Manager Chandler Birch will be onsite at the ASCO Annual Meeting. Join fellow oncology professionals in this...... -
May 24, 2023
Improving the Design of Clinical Trials in T1D: Analysis of Data from the Trial Outcome Markers Initiative (TOMI) Collaboration
With presentations from JDRF, TrialNet and the TOMI-T1D Collaboration The Trial Outcome Marker Initiative brings together data from many contributors in the field comprising more than 10,000 individuals with new onset T1D including 2900 from 21 different clinical trials. Analysis of C-peptide, HbA1c and as well as composite outcomes will be discussed which has provided......